Lipids & metabolic liver disease
Glycodeoxycholic Acid Inhibits Primary Bile Acid Synthesis With Minor Effects on Glucose and Lipid Homeostasis in Humans
Authors' conclusion
GDCA administration leads to elevated FGF19 levels and effectively inhibits primary bile acid synthesis, supporting therapy compliance and its effectiveness. However, effects on lipid, glucose, and energy metabolism were minimal, indicating that expanding the pool of this relatively hydrophobic bile acid does not impact energy metabolism in healthy subjects.
Study context
- Population
- Healthy lean men
- Participants
- 10 vs 10
- Comparison
- Oral GDCA 10 mg/kg/day in regular vs slow-release capsules
- Regular capsulesn = 10
- Slow-release capsulesn = 10
- Outcome
- Bile acid and metabolic effects of GDCA
- Follow-up
- 30 days
Main finding
As reported in the abstract
30 days
- GDCA increased postprandial total bile acid and FGF19 concentrations while suppressing primary bile acids chenodeoxycholic acid and cholic acid
- Plasma 7α-hydroxy-4-cholesten-3-one reduced, indicating repressed hepatic bile acid synthesis
- Minimal effects on indices of lipid, glucose and energy metabolism
Safety
Adverse events
Gastrointestinal adverse events
- Adverse events — Mild increases in plasma liver transaminases
- 50% of participants
Adverse events
- No serious adverse events in either capsule type
Original publication
Glycodeoxycholic Acid Inhibits Primary Bile Acid Synthesis With Minor Effects on Glucose and Lipid Homeostasis in Humans. J Clin Endocrinol Metab. Published 12 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →